Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Summary

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Psychosis Associated With Alzheimer's Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

55 to 90 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Last updated on ClinicalTrials.gov

September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites